Results 361 to 370 of about 521,863 (391)
Some of the next articles are maybe not open access.
Porokeratosis and immunosuppression
British Journal of Dermatology, 1995Immunosuppression may favour the development of disseminated superficial porokeratosis (DSP). We report the clinical features and the outcome of DSP in 24 patients receiving immunosuppressive treatment (group A), and compare the characteristics of the disease with those of 13 immunocompetent patients with DSP (group B). The two groups were similar with
Ruggero Caputo +4 more
openaire +3 more sources
[Pharmacogenetics of immunosuppressants].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015Individualized drug therapy with immunosuppressants is an hot topic in transplantation. Therapeutic drug monitoring (TDM) is currently utilized to guide therapy, but toxic or subtherapeutic concentrations can only be identified after the drug is administered.
Cojutti P. G., Baraldo M.
openaire +3 more sources
Principles of Immunosuppression
Critical Care Clinics, 1990One-year graft survival rates of 80% to 90% can now be achieved routinely for primary cadaveric transplants with a variety of CSA-containing regimens. Further improvement of these excellent results may be difficult because large numbers of patients must be evaluated to provide meaningful conclusions.
Daniel M. Canafax +3 more
openaire +3 more sources
Current Opinion in Immunology, 1992
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Immunosuppression—An overview
Seminars in Veterinary Medicine and Surgery: Small Animal, 1997The therapy of immune-mediated diseases in dogs and cats requires effective immunosuppressive therapy. The ideal therapy would suppress the abnormal (anti-self) immune responses while leaving the normal (anti-pathogen) immune responses intact. Unfortunately, such a therapy is not readily available.
openaire +3 more sources
Current Opinion in Organ Transplantation, 2012
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources
Elika, Derek, Kiran, Dhanireddy
openaire +2 more sources
Mechanisms of immunosuppression
Veterinary Immunology and Immunopathology, 1991Immunosuppresive disease is a major economic concern in domestic poultry production. Although many immunosuppressive agents have been described, mechanisms of how infectious and noninfectious agents compromise the immune system are poorly understood in avian species. Two categories, generalized and antigen-specific immunosuppression have been described
openaire +3 more sources
Immunosuppression and ablastin
Experimental Parasitology, 1975Abstract Ablastin formed by animals in response to infections by rodent trypanosomes possesses the characteristics of an antibody. Partial resistance to Trypanosoma lewisi is demonstrable in animals previously injected with live Trypanosoma musculi . Antisera from T. musculi infected mice do not inhibit reproduction by T.
openaire +3 more sources
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Nature Reviews Clinical Oncology, 2019Y. Togashi, K. Shitara, H. Nishikawa
semanticscholar +1 more source